News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

13th Mar 17

Synairgen Collaboration Progress

Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to report progress from its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase-like 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis and other fibrotic conditions.

On Friday UK time Synairgen announced data from an in vivo preclinical model of lung fibrosis.

Refer to the Synairgen media release.

Read full media release - pdf
23rd Feb 17

Pharmaxis Completes Treatment Phase in Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that the last of 423 patients has concluded treatment in its international clinical trial evaluating Bronchitol® (mannitol) for cystic fibrosis (CF). The topline results of the trial are expected to be reported in the second quarter of this year.

The Phase 3 trial known as DPM-CF-303 has been conducted in accordance with the requirements of the US Food and Drug Administration (FDA) to gain marketing approval for Bronchitol to treat adult CF patients in the United States. Subject to a positive trial outcome, a response will be submitted to the FDA and a decision on approval can be expected in the second half of 2018.

Read full media release - pdf
15th Nov 16

Pharmaxis Announces Research Collaboration with Woolcock Institute on Novel Cystic Fibrosis Therapy

Pharmaceutical research company Pharmaxis is pleased to announce a research collaboration with Sydney’s prestigious Woolcock Institute of Medical Research to develop a novel inhalation therapy for the treatment of cystic fibrosis (CF).

The National Health and Medical Research Council (NHMRC) has awarded a research grant of $421,545 for development and testing of the Orbital® Inhaler with a dry powder formulation of the antibiotic tobramycin. The Orbital inhaler is a Pharmaxis invention which has been designed to deliver high-doses of dry powder drugs to the lungs in a more effective and convenient manner than existing technology.

The project will be led by Woolcock Institute Deputy Director and Head of Respiratory Technology Professor Paul Young along with Professors Daniela Traini and Scott Bell.

Read full media release - pdf